 CAESAREA, Israel , May 11, 2022 PRNewswire -- IceCure Medical Ltd. NASDAQ: ICCM TASE: ICCM IceCure or the Company, developer of minimally-invasive cryoablation technology, the ProSense System, that destroys tumors by freezing as an alternative to surgical tumor removal ProSense, today announced it will report its business and financial results for the first quarter ended March 31, 2022 on Wednesday, May 18, 2022 with a press release issued at 7:00 am ET. 